(Q37598944)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Els Lierman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

1 reference

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

1295-1304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

7 February 2020

cites work

1 reference

The hypereosinophilic syndromes: current concepts and treatments

21 January 2018

1 reference

Recent advances in pathogenesis and management of hypereosinophilic syndromes

21 January 2018

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

21 January 2018

1 reference

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders

21 January 2018

1 reference

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion

21 January 2018

1 reference

Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).

21 January 2018

1 reference

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

21 January 2018

1 reference

Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase

21 January 2018

1 reference

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent

21 January 2018

1 reference

Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study

21 January 2018

1 reference

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

21 January 2018

1 reference

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

21 January 2018

1 reference

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

21 January 2018

1 reference

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

21 January 2018

1 reference

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

21 January 2018

1 reference

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia

21 January 2018

1 reference

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

Activation of tyrosine kinases by mutation of the gatekeeper threonine

21 January 2018

1 reference

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions

21 January 2018

1 reference

Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia

21 January 2018

1 reference

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

21 January 2018

1 reference

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

21 January 2018

1 reference

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

21 January 2018

1 reference

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

21 January 2018

1 reference

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

21 January 2018

1 reference

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

21 January 2018

1 reference

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.

21 January 2018

1 reference

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

21 January 2018

1 reference

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.

21 January 2018

1 reference

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

21 January 2018

1 reference

21 January 2018

1 reference

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease

21 January 2018

1 reference

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 January 2018

1 reference

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

21 January 2018

1 reference

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

21 January 2018

1 reference

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Histone modifications in transcriptional regulation

21 January 2018

1 reference

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

21 January 2018

1 reference

Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.

21 January 2018

1 reference

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

21 January 2018

1 reference

Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors

21 January 2018

1 reference

Treatment of hypereosinophilic syndrome with imatinib mesilate

21 January 2018

1 reference

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

21 January 2018

1 reference

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

21 January 2018

1 reference

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 January 2018

1 reference

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

21 January 2018

1 reference

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders

21 January 2018

1 reference

Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761433%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference